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doi:10.101An Assessment of the Effect of Human Herpesvirus-6
Replication on Active Cytomegalovirus Infection after
Allogeneic Stem Cell Transplantation
Nuria Tormo,1 Carlos Solano,2,3 Rafael de la Camara,4 Ana Garcia-Noblejas,4
Laura Carden˜oso,5 Marıa Angeles Clari,1 Jose Nieto,6 Javier Lopez,7
Juan Carlos Hernandez-Boluda,2 Marıa Jose Remigia,2 Isabel Benet,2 David Navarro1,8Human herpesvirus-6 (HHV-6) may enhance cytomegalovirus (CMV) replication in allogeneic stem cell
transplant (allo-SCT) recipients either through direct or indirect mechanisms. Definitive evidence supporting
this hypothesis are lacking.We investigated the effect of HHV-6 replication on active CMV infection in 68 allo-
SCTrecipients. Analysis of plasma HHV-6 and CMVDNAemiawas performed by real-time PCR. Enumeration
of pp65 and IE-1 CMV-specific IFNgCD81 andCD41 T cells was performed by intracellular cytokine staining.
HHV-6DNAemia occurred in 39.8%of patients, andwas significantly associatedwith subsequent CMVDNAe-
mia in univariate (P5.01), but not in multivariate analysis (P5.65). The peak of HHV-6DNAemiawas not pre-
dictive of the development of CMVDNAemia. Timing and kinetics of active CMV infectionwere comparable in
patients eitherwith orwithout a preceding episode of HHV-6DNAemia. The occurrence of HHV-6DNAemia
had no impact onCMV-specific T cell immunity reconstitution early after transplant. The receipt of a graft from
an HLA-mismatched donor was independently associated with HHV-6 (P5.009) and CMV reactivation
(P5.04). The data favor the hypothesis that a state of severe immunosuppression leads to HHV-6 and CMV
coactivation, but argue against a role of HHV-6 in predisposing to the development of CMV DNAemia or
influencing the course of active CMV infection.
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Active cytomegalovirus (CMV) infection is a fre-
quent event following allogeneic hematopoietic stem
cell transplantation (allo-SCT), which causes signifi-
cant morbidity and mortality [1]. Human herpesvirus
6 (HHV-6) is a member of the beta herpesvirus
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6/j.bbmt.2009.12.003related to clinical complications, such as delayed
neutrophil and platelet engraftment, interstitial pneu-
monia, skin rash, severe graft-versus-host disease
(GVHD), central nervous system disorders, and overall
mortality [2]. Depending on the method used for the
surveillance of viral replication and the net state of post-
transplant immunosuppresion, 45% to 85%, and 25%
to 80%of allo-SCT recipients experience 1 ormore ep-
isodesof activeCMVorHHV-6 infection, respectively,
within the first 100 days after transplantation [1,2].
HHV-6 is considered an immunomodulatory and im-
munosuppressive agent [3], and thereby might increase
the risk of active CMV infection and disease in the
transplantation setting. Epidemiologic, clinical, and vi-
rologic evidence supporting this assumption has been
mainly reported in solid organ transplant recipients. It
was shown that occurrence ofHHV-6 viremiawas asso-
ciatedwith an increased risk of subsequentdevelopment
of either CMV syndrome or CMV end-organ disease
[4-9]. The pathophysiologic basis of such viral interac-
tion is largely unknown, but it might be related to the
ability of HHV-6 to induce the synthesis of proinflam-
matory cytokines, such as interleukin-1aˆ and tumor ne-
crosis- a, known to trigger CMV reactivation, and to653
Table 1. Characteristics of Patients
Parameter Value
Patients 68
Age, years 45 (18–70)
Sex, male/female 37/31
Underlying disease
Acute myelogenous leukemia 25 (36.7)
Acute lymphoblastic leukemia 10 (14.7)
Non-Hodgkin lymphoma 8 (11.8)
Hodgkin lymphoma 5 (7.4)
Plasma cell disorders 4 (5.9)
Chronic lymphocytic leukemia 4 (5.9)
Chronic myelogenous leukemia 3 (4.4)
Myelodysplastic syndrome 2 (2.9)
Severe aplastic anemia 1 (1.5)
Others 6 (8.8)
Cytomegalovirus serostatus
D+/R + 39 (57.3)
D–/R+ 21 (30.8)
D–/R– 6 (8.8)
654 Biol Blood Marrow Transplant 16:653-661, 2010N. Tormo et al.suppress T-lymphocyte function [3]. The effect of
HHV-6 replication on CMV infection in the allo-
SCT setting and the clinical consequences of such in-
teraction, if any, remain imprecisely defined. In a recent
report, Wang et al. [10] provided data suggesting that
HHV-6 reactivation might suppress the reconstitution
of CMV-specific lymphoproliferative responses,
thereby promoting CMV replication. The present
study was undertaken to determine whether active
HHV-6 infection predisposes to CMV reactivation
and/or has any influence on the kinetics of CMV repli-
cation in the allo-SCT setting. The elucidation of the
nature of the pathogenetic interaction between both
beta herpesviruses may have important implications
in the therapeuticmanagement ofCMV infection in re-
cipients of allo-SCT.D+/R– 2 (2.9)
Donor type
HLA-identical sibling 30 (44.1)
Mismatched related donor 6 (8.8)
Matched unrelated donor 19 (27.9)
Mismatched unrelated donor 13 (21.6)
Conditioning regimen
Nonmyeloablative 40 (58.8)
Myeloablative 28 (41.2)
Stem cell source
Peripheral blood 53 (77.9)
Umbilical cord blood 13 (19.11)
Bone marrow 2 (2.9)
GvHD prophylaxis
Cyclosporine A + methotrexate 33 (48.5)
Cyclosporine A + MMF 15 (22.0)
Cyclosporine A + prednisone 14 (20.5)
Others 6 (8.8)
Acute GVHD incidence*
Grades 0–I 45 (66.1)
Grades II–IV 23 (33.9)
GVHD indicates graft-versus-host disease; MMF, mycophenolate
mofetil; D, donor; R, recipient; +, CMV seropositive; –, CMV seronega-
tive; HHV-6, human herpesvirus-6.
Age is given as median (range).
*Incidence of acute GVHD by day +100 posttransplant.PATIENTS AND METHODS
Patients
Patients undergoing allo-SCT betweenNovember
2005, and December 2008, at the following hospitals:
Hospital Clınico Universitario,Valencia, Hospital La
Princesa, Madrid, Hospital Morales Meseguer, Mur-
cia, andHospital Ramon y Cajal, Madrid, were eligible
for inclusion. The study was approved by all ethics
committees. All patients gave their informed consent
to participate in the study. Sixty-eight allo-SCT recip-
ients were included and followed up until day 100 after
transplantation. Relevant demographic and clinical
data of these patients are shown in Table 1.
Definitions
Neutrophil and platelet engraftment were defined
as:.500 cells/mL for 3 days, and.50,000 platelets/mL
for 1 week in the absence of platelet transfusion, re-
spectively, counting the first day as the day of engraft-
ment [11]. The intensity of acute GVHD (aGVHD)
was graded from 0 to IV (0 to I, low grade, and II to
IV, high grade), as previously described [11].
Virological Monitoring and Management
of Active CMV Infection
Patients were monitored for pp65 antigenemia by
a commercial immunofluorescence assay (Light Diag-
nostics CMV pp65 Antigenemia Immunofluores-
cence assay, Chemicon International, Temecula, CA,
USA), and plasma DNAemia (CMV real-time PCR,
Abbott Molecular, Des Plaines, IL, USA) once a week,
as previously reported [12,13]. The surveillance of
HHV-6 DNAemia was not routinely performed in our
patients. Thus, cryopreserved specimens were used for
analysis.The availability of a sufficient volumeofplasma
for PCRwas a limiting factor that precluded the analysis
of a larger number of specimens. Sequential plasmasamples frompatients had been collected from amedian
of 7days (range: 0-26days) toamedianof58days (range:
38-75 days) after transplant. A total of 520 samples
(a median of 6 samples per patient; range: 3-11 samples)
were analyzed. HHV-6 DNA detection was performed
by a commercial real-time PCR assay (HHV-6 Q-PCR
Alert Amplimix, Nanogen Advanced Diagnostics,
Torino, Italy) on a Smart Cycler instrument (Cepheid,
Sunnyvale, CA, USA). DNA was extracted from a vol-
umeof 200mLof plasmaon theBioRobotEZ1worksta-
tion (EZ1 virus Mini Kit v2.0, Qiagen, Hamburg,
Germany). This assay amplifies a sequence within
ORF 13R common to HHV-6 variants A and B. The
lower limit of detection of the assay is 10 copies/mL,
and the linear measuring range is 6 log10 copies/mL.
For data analysis, the commencement and end of a given
episode of active viral infection were defined by the first
positive (any level of plasma viral load) and first negative
results, respectively, in the corresponding PCR assay.
Biol Blood Marrow Transplant 16:653-661, 2010 655HHV-6 and CMV in Allo-SCT RecipientsActiveHHV-6 orCMV infectionwas definedby the de-
tection of viral DNA in 1 or more plasma specimens.
Preemptive therapy with oral valganciclovir (900 mg/
12 hours) or i.v. ganciclovir (5 mg/lg/12 hours) was ini-
tiated upon a positive antigenemia result ($1 pp65 pos-
itive cells/200,000 cells) and discontinued following 2
consecutive negative antigenemia results obtained 3 to
7 days apart, after a minimum of 2 weeks of treatment.
Foscarnet (i.v. 60 mg/kg/12 hours) was used instead of
ganciclovir in patients with severe neutropenia. All pa-
tients with antibodies against herpes simplex virus re-
ceived oral acyclovir prophylaxis following the
institutional protocols.
Viral Doubling Time Calculation
To determine the rate of virus replication, the viral
doubling time (dt) of HHV-6 and CMV was estimated
following 2 approaches. In the first, we considered for
analysis the first 2 PCR-positive results. The dt was
given by dt5 (t2 2 t1)  log(2)/log(q2/q1), with q1
and t1 being the DNAemia level (copies/mL) at the
time of the first positive PCR (in days) respectively,
and q2 and t2 theDNAemia level at the time of the sec-
ond measurement, respectively. This formula assumes
a constant growth rate, which occurs in the early phase
of virus replication. When more than 2 positive PCR
results were available, the peak DNAemia value was
not considered, as the growth rate of a virus slows as
the viral load approaches its peak. In the second ap-
proach, we included in the analysis all measurements
from the last negative PCR result to the peak viral
load, and estimated the dt as dt5 ln(2)/k, with k being
the rate constant for exponential growth, which is
given by V(t)5V(0)xekt, where V is the viral load and
t the time (in days) [14]. For CMV, the dt was calcu-
lated on the basis of DNAemia values obtained prior
to initiation of preemptive therapy. Thus, only epi-
sodes in which the PCR turned positive (at least 2 con-
secutive samples) earlier than the antigenemia assay
and those resolving without the implementation of
preemptive therapy (antigenemia negative episodes)
were taken into consideration for analysis. Likewise,
for calculation of the HHV-6 dt only viral loads mea-
sured in the absence of (val)ganciclovir therapy were
taken into consideration for analysis.
Immunological Monitoring
Enumeration of pp65 and IE-1 CMV-specific
IFNg-producing CD81 and CD41 T lymphocytes
was carried out by flow cytometry for ICS (BD Fastim-
mune, BD-Beckton Dickinson and Company-Biosci-
ences, San Jose, CA, USA) as described previously
[15]. Whole blood was simultaneously stimulated
with 2 sets of 15-mer overlapping peptides encompass-
ing the sequence of pp65 and IE-1 CMV proteins
(2 mg/mL/peptide), obtained from JPT peptideTechnologies GmbH (Berlin, Germany), in the pres-
ence of 1 mg/mL of costimulatory monoclonal anti-
bodies (mAbs) to CD28 and CD49d for 6 hours at
37 C. Brefeldin A (10 mg/mL) was added for the last
4 hours of incubation. Cells were permeabilized and
stained with a combination of labeled mAbs (anti-
IFNg-FITC, anti-CD69-PE, anti-CD4, or CD8-
PerCP-Cy5.5 and anti-CD3-APC when the IFNg
CD81 kit was used). Cells were analyzed on a FACS-
Calibur flow cytometer using CellQuest software
(BD Biosciences Immunocytometry Systems). CD41
and CD81 events were gated and then analyzed for
the CD69 activation marker and IFNg production.
The total number of CMV-specific CD41 and
CD81 T cells was calculated by multiplying the per-
centages of CMV-specific T cells producing IFNg
upon stimulation (after background substraction) by
the absolute CD41 and CD81 T cell counts. The spe-
cific responses were considered those .0.1% for both
CD41 and CD81 T cells.Statistical Analysis
Data were analyzed with the aid of the statistical
package SPSS (version 15.0). Frequency comparisons
were carried out using thec2 test for categoric variables
(univariate analysis), and the nonparametric Mann-
Whitney U test for unpaired continuous data. The
Spearman rank test was used for analyzing the correla-
tion between continuous variables. For multivariate
analysis, variables associated (P\ .10) with HHV-6
DNAemia in univariate analysis were included and an-
alyzed using a binary logistic regression model. Vari-
ables that were associated with CMV DNAemia in
the univariate analysis were included and analyzed us-
ing a Cox proportional hazards regression modeling,
in which HHV-6 DNAemia was entered as a time-de-
pendent variable. The potential associations between
HHV-6 DNAemia and neutrophil and platelet en-
graftment, and between HHV-6 or CMV DNAemia
and the incidence of high grade (II-IV) aGVHD were
also evaluated by Cox proportional hazards regression
analysis, both virologic events being considered as
a time-dependent variables. Results are expressed as
relative risk ratios (RRs) or hazard ratios (HRs), and
their corresponding 95% confidence interval (CI). A
P value\.05 was considered significant.RESULTS
Incidences and Kinetics of Active HHV-6
Infection
Sixty-eight nonconsecutive patients at the Hospi-
tal Clınico Universitario, Valencia (n 5 53), and the
Hospital de la Princesa, Madrid (n5 15) were finally
included in the study. In 62 of the 68 patients, the first
Days after transplant
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Figure 1. Kinetics of human herpesvirus 6 (HHV-6) plasmaDNAemia in
27 allogeneic stem cell transplant recipients who had 1 or more positive
results by a real-time PCR (lower detection limit, 10 DNA copies/mL).
656 Biol Blood Marrow Transplant 16:653-661, 2010N. Tormo et al.specimen subject to analysis was obtained within the
first 10 days after transplant. HHV-6 DNAemia was
detected at least once in 27 of 68 patients (39.7%),
a median of 20 days (range: 7- 44 days) after transplan-
tation. A median of 2 positive samples (range: 1-5 sam-
ples) per patient was found. Six patients had a single
positive PCR result. To rule out the possibility of
DNA contamination, a second aliquot of plasma
from these 6 patients was analyzed. All these samples
tested positive again and displayed comparable
HHV-6 DNA loads (not shown).
The kinetics of HHV-6DNAemia in our patients is
shown in Figure 1. The peak level ofHHV-6DNAemia
(median 345 copies/mL, range: 26-13,661 copies/mL)
was reached more frequently in the fourth week
(52%). Episodes of HHV-6 DNAemia lasted a median
of 10 days (range: 3-35 days). Self-clearance of HHV-6
DNAemiawas observed in19of 27 episodes.Resolution
of the remaining 8 episodes of HHV-6 DNAemia oc-
curred while patients were on (val)ganciclovir therapy,
which was initiated because of the development of anti-
genemia-positive active CMV infection. In 3 of these 8
episodes, preemptive therapy was initiated at the time
of peakHHV-6DNAemia. In the remaining 5 episodes,
preemptive therapy was implemented once HHV-6
DNAemia had begun to decrease.Relationship between HHV-6 and CMV
DNAemia
Thirty-nine patients (57.3%) experienced an epi-
sode of active CMV infection within the first 100
days after transplant (median onset of the episodes
34 days, range: 0-70 days). None of these patients pro-
gressed to CMV disease within the study period.
Twenty-seven of the 39 episodes were preemptively
treated, as the antigenemia assay turned positive.
The remaining 12 episodes resolved spontaneously.
No PCR negative/antigenemia positive episodes
were observed. In all episodes, the plasma PCR assay
turned positive earlier than the antigenemia assay.
Twenty-one of the 39 patients had prior or concom-
itant HHV-6 DNAemia. In 20 of 21 patients, detection
ofHHV-6DNAemia preceded that ofCMVDNAemia
byamedianof 15days (range: 2-50days).The remaining
18 patients developingCMVDNAemia had noHHV-6
DNA detected in plasma.HHV-6 and CMVDNAemia
overlapped in 11 of the 21 patients. In the remaining 10
patients, CMV DNAemia was detected after HHV-6
DNAemia clearance.
The peak level of HHV-6 DNAemia in patients
who subsequently experienced an episode of active
CMV infection (median 190 copies/mL, range:
26-13,661 copies/mL), and that in patients who did
not develop it (median 214 copies/mL, range: 65-478
copies/mL) were not significantly different (P5 .85).
The kinetics profile of CMV DNAemia in patientswith or without a preceding episode of HHV-6
DNAemia was next investigated. As shown in Table
2, we found no significant differences between the
groups in terms of the time to the first CMVPCR-pos-
itive result, the day of initiation of preemptive treat-
ment and its duration, the initial antigenemia and
DNAemia values, the peak viral load, the duration of
DNAemia, and the number of preemptively treated
or self-resolving episodes. Furthermore, no significant
correlation (P5 .43) was found between the peak
levels of HHV-6 and CMV DNAemia.
Doubling Times of HHV-6 and CMV
As a complementary approach to assess the effect of
active HHV-6 infection on CMV replication, we esti-
mated the rate of CMV replication in patients with or
without a preceding episode of HHV-6 DNAemia. As
explained in the methods section, we used 2 different
approaches and obtained comparable results (not
shown). Data are depicted in Figure 2. The median dt
of HHV-6 was 0.90 days, ranging from 0.2 to 1.71
days, which was significantly (P # .001) shorter than
that of CMV (median 1.72 days, range: 0.60-12.8
days). The median dt of CMV in patients with prior
HHV-6 DNAemia was 1.72 days (range: 0.90-12.8
days), and did not differ significantly (P5 .64) from
that in patientswith nodocumentedHHV-6DNAemia
(median 1.56 days, range: 1.07-8.50 days). The latter 2
subgroups of patientswerematched for donorCMVse-
rostatus, donor type (related/unrelated; matched/mis-
matched), source of stem cells and conditioning, and
GVHD prophylaxis regimens (not shown).
Effect of Active HHV-6 Infection
on CMV-Specific Immune Reconstitution
Early after Transplant
We investigated whether the occurrence of active
HHV-6 infection had any measurable effect on the
Table 2. Active CMV Infection Profile in Patients with or without a Preceding Episode of HumanHerpesvirus 6 (HHV-6) DNAemia
HHV-6 DNAemia
Virologic Parameter Yes (n5 21) No (n5 18) P Value*
First CMV PCR
Positive, day 29 (6-66) 36 (0-70) .95
Initial CMV load in copies/mL 41 (25-2300) 45 (25-7276) .71
Peak CMV load in copies/mL 1207 (25-212,320) 1302 (25-65,945) .90
Duration CMV
DNAemia, days 29 (5-100) 24 (3-98) .91
Initiation of preemptive therapy, days 36 (24-67) 36.5 (12-96) .21
Initial antigenemia value (positive cells/200,000 PMNLs) 3 (1-210) 3 (1-50) .46
Self-resolving episodes† 5 6 .51
Duration of preemptive treatment 22 (14-60) 26.5 (14-90) .71
CMV indicates cytomegalovirus; PCR, polymerase chain reaction; PMNL, polymorphonuclear leukocytes.
Figures are given as median numbers (range).
*Analysis performed by use of Mann-Whitney U-test.
†Episodes of CMV DNAemia resolved without implementation of preemptive therapy.
Biol Blood Marrow Transplant 16:653-661, 2010 657HHV-6 and CMV in Allo-SCT Recipientsrecovery of pp65 and IE-1-specific IFNg-CD81 and
IFNg CD41 T cell responses early after transplant
(median 32 days; range: 26–48 days). As shown in
Table 3, overall, peripheral counts of both T cell sub-
sets in patients experiencing HHV-6 DNAemia prior
to day 30 were not significantly different from those
in patients with no documented HHV-6 DNAemia.
We performed a similar analysis on 2 subgroups of pa-
tients: 1 including patients not developing active CMV
infection during the follow-up period (n5 23), of
whom 6 had HHV-6 DNAemia and 17 did not, and
the other including patients who developed an active
CMV infection beyond day 30 posttransplant
(n5 14), of whom 6 had a preceding episode of
HHV-6 DNAemia and 8 did not. Again, we found
comparable levels of both CMV-specific T cell subsets
in both subgroups, irrespective of whether a precedingCMV
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Figure 2. Doubling times (dt) in days of human herpes virus 6 (HHV-6)
and cytomegalovirus (CMV). The dts of CMV in patients with a preceding
episode of HHV-6 DNAemia and in those with no documented HHV-6
DNAemia are represented separately in the right columns. Horizontal
bars represent median values.episode of HHV-6 DNAemia had been documented
or not.
We also assessed whether occurrence of HHV-6
DNAemia had any effect on the magnitude of the
CMV-specific immune response elicited by CMV rep-
lication. Blood samples drawn at a median of 63 days
(range: 56-74 days) after transplant were available
from 14 patients developing active CMV infection
within 30 to 60 days after transplant. Seven of these pa-
tients had an episode of HHV-6 DNAemia preceding
that of active CMV infection. Median IFNg-CD81
and IFNg CD41 T cells in these patients (0.44 cells/
mL, and 0.34 cells/mL, respectively) did not differ sig-
nificantly (P5 .23) from that in patients with no prior
episode of HHV-6 DNAemia (0.28 cells/mL, and 0.24
cells/mL).Risk Factors for HHV-6 and CMV DNAemia
In our cohort, receipt of a graft from an unrelated
or and HLA-mismatched donor, the use of umbilical
cord blood as a source of hematopoietic stem cells,
myeloablative conditioning, and the use of prednisone
in GVHD prophylaxis were significantly associated
with the occurrence of HHV-6 DNAemia in the uni-
variate analysis (Table 4). Other covariates such as
age, sex, underlying disease, and donor CMV serosta-
tus were not associated with HHV-6 DNAemia (not
shown). In the multivariate analysis, the source of
stem cells and the receipt of a graft from an unrelated
or an HLA-mismatched donor were independently
associated with HHV-6 DNAemia (Table 4).
Theunivariate analysis identified several risk factors
significantly associated with the occurrence of CMV
DNAemia: receipt of a graft from anHLA-mismatched
donor (RR5 1.5, 95%CI, 1.1-2.4, P5 .04) or an unre-
lateddonor (RR5 1.6, 95%CI, 1.0-2.4,P5 .01), useof
prednisone in GVHD prophylaxis regimen (RR5 1.8,
95%CI, 0.6-5.0,P5 .00), andpriorHHV-6DNAemia
(RR5 1.6, 95% CI, 1.1-2.4, P5 .01). Nevertheless, in
Table 3. Early Reconstitution (day +30) of pp65 and IE-1-
Specific IFNg-Producing CD8+ and CD4+T Cells in Patients
Either Experiencing or Not human Herpesvirus 6 (HHV-6)
DNAemia
Patient Group
HHV-6
DNAemia
No HHV-6
DNAemia P Value*
All patients†
IFNg CD8+ 0.30 (0-1.54) 0.11 (0-3.11) .52
IFNg CD4+ 0.32 (0-1.54) 0.18 (0-7) .54
No CMV DNAemia prior to
day +100‡
IFNg CD8+ 0.92 (0-1.54) 0.42 (0-3.11) .83
IFNg CD4+ 0.78 (0-3.76) 0.59 (0-7) .66
CMV DNAemia beyond day +30§
IFNg CD8+ 0.26 (0-0.56) 0 (0-0.42) .18
IFNg CD4+ 0.20 (0-1.02) 0.04 (0-0.32) .34
CMV indicates cytomegalovirus.
Figures are cells/mL blood, and are given as median numbers (range).
*Analysis performed by use of Mann-Whitney U-test.
†All 37 patients either experiencing or not CMV DNAemia.
‡This group included 23 patients, of whom 17 developed HHV-6
DNAemia prior to day 30 posttransplant and 6 did not.
§This group included 14 patients, of whom 6 developed HHV-6
DNAemia prior to day 30 posttransplant and 8 did not.
658 Biol Blood Marrow Transplant 16:653-661, 2010N. Tormo et al.the multivariate analysis, in which HHV-6 DNAemia
was introduced as a time-dependent variable, only the
receipt of a graft from an HLA-mismatched donor
retained significance (Table 5).
HHV-6 DNAemia, CMV DNAemia, and Clinical
End Points
We investigated whether HHV-6 DNAemia had
any effect on the time to neutrophil and platelet en-
graftment. All but 1 patient had achieved neutrophil
engraftment by day130, whereas 80% and 92% of pa-
tients had achieved platelet engraftment by days 130
and 150, respectively. Only patients displaying
HHV-6 DNAemia before day 130 (25 of 27 patients)
were included for analysis. The occurrence of HHV-6
DNAemia had no significant effect on neutrophil en-
graftement by day 130 (HR, 1.0; 95% CI, 0.8-1.7;
P5 .85), or platelet engraftment by day 130 (HR,
0.9; 95% CI, 0.7-2.1; P5 .36) or by day 150 (HR,
1.1; 95% CI, 0.6-2.7; P5 .54).
We also assessed the potential effect of HHV-6
and CMVDNAemia in the development of high gradeTable 4. Analysis of Risk Factors Associated with the
Development of Human Herpesvirus 6 (HHV-6) DNAemia
RR (95% CI) P Value
Risk Factor Univariate Multivariate
Unrelated donor 4.5 (1.9-10.7) .00 1.7 (0.4-3.1) .01
HLA mismatched donor 2.5 (0.8-7.4) .00 1.8 (0.7-3.8) .00
Myeloablative conditioning 2.4 (1.3-4.4) .03 1.2 (0.5-1.4) .08
Cord blood graft 3.3 (2.1-5.3) .00 1.8 (0.4-3.3) .00
Prednisone in GVHD
prophylaxis 1.5 (0.5-4.3) .00 1.2 (0.6-1.9) .21
RR indicates relative risk ratio (95% confidence interval); GVHD,
graft-versus-host disease.(II to IV) aGVHD by day 1100 after transplantation.
Both virologic events were considered for analysis only
if they preceded the occurrence of the clinical end
point. Grades II-IV aGVHD occurred in 7 of 24
patients with no evidence of HHV-6 and CMV
DNAemia, and in 16 out of 44 patients who developed
either HHV-6 DNAemia, CMV DNAemia, or both.
Neither HHV-6 DNAemia (HR, 0.9; 95% CI, 0.3-
1.9; P5 .6) nor CMV DNAemia (HR, 0.8; 95% CI,
0.2-2.1) were significantly associated with subsequent
development of high grade aGVHD.
No clinical events potentially associated with
HHV-6 reactivation in allo-SCT recipients (CNS dys-
function, idiopathic pneumonia syndrome, or skin rash
not because of GVHD) were observed in our cohort.
In addition, we sought to determine whether the oc-
currence of HHV-6 DNAemia, CMV DNAemia, or
both had any influence on all-cause mortality during
the study period. Eleven patients had died by 1100
(5 because of severe aGVHD, 4 because of relapse,
and 2 as a result of a systemic infection). Of the 11 pa-
tients, 4 had no documented HHV-6 or CMVDNAe-
mia, 5 had only CMV DNAemia, and 2 displayed
HHV-6 and CMV DNAemia. The scarce number of
clinical events precluded any meaningful statistical
analysis.DISCUSSION
In our cohort of allo-SCT recipients, almost 40%
of patients experienced HHV-6 DNAemia, which oc-
curred most frequently around the time of engraft-
ment. This percentage might have been even higher
as we could not rule out the occurrence of HHV-6
DNAemia very early after transplant in a couple of pa-
tients from whom no plasma samples drawn within the
first 4 weeks after transplantation were available for
analysis. Incidence rates of active HHV-6 infection
ranging from 28% to 78% have been published
[11,16-28]. Discrepancies among these studies are
likely due to variations in the laboratory method and
type of specimen employed for detecting HHV-6,
the frequency of virologic monitoring and the clinical
characteristics of the patients. We used a highly sensi-
tive real-time PCR assay and plasma instead of leuko-
cytes for quantification of HHV-6 DNAemia.
Although it remains a matter of debate [25,29], the
level of plasma HHV-6 DNAemia appears to reliably
reflect the degree of viral systemic replication. In our
cohort, HHV-6 variant B was implicated in all epi-
sodes (n5 16) analyzed (not shown), and the kinetics
of DNAemia was not suggestive of HHV-6 genome
integration [30].
In accordance with previous reports [19,21,25,31],
the receipt of a graft from an unrelated or HLA-mis-
matched donor and the use of umbilical cord blood as
Table 5. HHV-6 DNAemia as a Risk Factor for the
Development of Cytomegalovirus (CMV) DNAemia
Risk Factor HR (95% CI) P Value
Unrelated donor 1.8 (0.7-4.6) .18
HLA mismatched donor 4.7 (1.1-21.5) .04
Prednisone in GVHD
prophylaxis 1.2 (0.7-1.9) .40
HHV-6 DNAemia 1.2 (0.5-2.7) .65
HR indicates hazard ratio (95% confidence interval [CI]); GVHD,
graft-versus-host disease.
Analysis was performed by Cox proportional hazards regression.
HHV-6 DNAemia was included as a time-dependent variable.
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with the development of HHV-6 DNAemia.
The kinetics of HHV-6 DNAemia in our patients
was comparable with that reported in other series
[11,19-22,24-27]. That is, peak incidences occurring
within the second and third weeks after transplant,
peak viral load being reached within 3 to 4 weeks post-
transplant, and median duration of episodes\2 weeks.
In our setting, most episodes were self-limited, that is,
they resolved without the implementation of antivirals
with activity against HHV-6, such as (val)ganciclovir.
This appears to be themost frequent outcome of active
HHV-6 infection in patients with low to intermediate
levels of HHV-6 DNAemia [32], as those in our series.
The peak plasma levels of HHV-6 DNAemia in our
patients were comparable with those reported by
Zerr et al. [11], but markedly lower than those pub-
lished by Ogata et al. [25]. Again, differences in the
characteristics of patients and/or in the method used
for HHV-6 DNA quantification may account for this
discrepancy.
Contradictory data have been reported on the in-
fluence of HHV-6 DNAemia on the time to neutro-
phil and platelet engraftment [11,19,25,26]. In our
cohort, we observed no effect of HHV-6 DNAemia
in neutrophil engraftment by day130, and platelet en-
graftment by days 130 and 150. The limited number
of events included in our analysis does not allow us to
draw definitive conclusions on this matter. We also
found no significant association between the occur-
rence of HHV-6 or CMV DNAemia and an increased
risk of development of high grade (II to IV) aGVHD.
This association has been previously documented for
HHV-6 [11,33], but not for CMV [33]. Again, the
scarce number of clinical events included minimizes
the significance of our analysis.
HHV-6 is known to display immunomodulating
and immunosuppressive properties, and thereby it
may lead to enhanced CMV replication [4]. In this
context, HHV-6 replication has been related to an in-
creased risk of active CMV infection and disease in
solid organ transplant recipients [4-9]. Nevertheless,
little is known about the biologic and clinical
consequences of the interaction between both betaherpesviruses in the allo-SCT setting. Should the
role of HHV-6 in promoting CMV replication be
proven, then the documentation of HHV-6 DNAemia
could become an indication for prophylaxis against
CMV infection to prevent or minimize the effects of
such an interaction. Previous studies showed that
allo-SCT recipients experiencing HHV-6 DNAemia
are more prone to subsequently developing an episode
of active CMV infection, as determined by blood cul-
ture, pp65 antigenemia or leukocytes or plasma CMV
DNAemia [10,19,23,24,25,26,28], although this asso-
ciation did not reach significance in all series. Yet,
there is no evidence of a relationship between active
HHV-6 infection and a higher risk for CMV disease.
In our series, an association between HHV-6 DNAe-
mia and the subsequent occurrence of CMV DNAe-
mia was observed, yet most episodes of HHV-6
DNAemia had been cleared spontaneously or were in
the process of resolution at the time of CMV DNAe-
mia detection. In fact, overlapping HHV-6 and
CMV DNAemia was only observed in around half of
patients. Interestingly, the peak level of HHV-6
DNAemia in patients who subsequently developed
an episode of CMV DNAemia was comparable with
that in patients who did not. Although this observation
argues against a direct role of HHV-6 in predisposing
to the development of active CMV infection, the pos-
sibility that active HHV-6 infection triggered CMV
reactivation by a direct interaction independent of
the viral load could not be definitely rule out.
We were interested in determining whether the
occurrence of HHV-6 DNAemia had any impact on
the pattern of active CMV infection. Our data do not
support this hypothesis. First, no correlation was
found between the peak levels of HHV-6 and CMV
DNAemia. Such a correlation would be expected in
a scenario where HHV-6 directly interacts with
CMV [9].Our observation is in keepingwith a previous
report [19], but in contrast to that of others [26]. In the
latter study, however, active CMV infection was mon-
itored by CMV antigenemia assay. Second, the occur-
rence ofHHV-6DNAemia had no apparent impact on
the kinetics of active CMV infection, as assessed by the
precocity of onset, initial, and peak levels of CMV
DNAemia and the viral doubling time. Furthermore,
the duration of CMV DNAemia was comparable in
patients with or without a preceding episode of
HHV-6 DNAemia. This observation was not biased
by a different use of val(ganciclovir) in either group,
as the number of episodes preemptively treated and
the duration of antiviral courses were not significantly
different between groups.
Our data are also against a role of HHV-6 in pro-
moting CMV replication by inhibiting the reconstitu-
tion of CMV-specific T cell immunity. In a previous
study, a trend for an inverse correlation between
HHV-6 viral load and the presence of CMV-specific
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previously showed that peripheral blood levels of
pp65 and IE-1 CMV-specific IFNg-producing
CD81 and CD41 T cells correlate with protection
against CMVDNAemia [15].Wemeasured peripheral
counts of both T cell subsets around day 30 posttrans-
plant in patients either experiencing an episode of
HHV-6 DNAemia prior to that time point or not de-
veloping it during the study period. We observed no
apparent effect ofHHV-6DNAemia on the level of re-
constitution of either T cell population, regardless of
whether CMV DNAemia subsequently developed or
not. As expected on the basis of previous investigations
of our group [15], lower levels of CMV-specific T cells
were seen in patients experiencing CMV DNAemia
than in those who remained free of it. Differences in
the type of specimen used for HHV-6 DNA detection,
the method for assessing the immune response against
CMV, or the timing of immunologic monitoring may
account for the discrepancy between our study and that
of Wang et al. [10]. We also observed that peripheral
levels of both T cell subsets by day 160 in patients
developing an episode of active CMV infection within
30 to 60 days after transplant were comparable in pa-
tients with or without a preceding episode of HHV-6
DNAemia. Taken together, the data indicated that oc-
currence of HHV-6 DNAemia had no effect either in
the reconstitution of CMV-specific immunity or in the
magnitude of the CMV-specific immune response eli-
cited by CMV replication. It remains to be determined
whether the occurrence of HHV-6 DNAemia has an
effect on recovery of CMV-specific immunity at later
times after transplant.
The temporal association between HHV-6 and
CMV DNAemia may just be the result of a severe im-
munosuppressive condition of patients that triggers vi-
ral coactivation, and not necessarily because of their
interaction. In line with this assumption, we found
the receipt of a graft from an HLA-mismatched donor
being independently associated with the occurrence of
either HHV-6 or CMV DNAemia in our cohort.
Moreover, in the multivariate model, including risk
factors that were associated significantly with the de-
velopment of CMV DNAemia in the univariate analy-
sis, HHV-6 DNAemia did not retain significance,
although a trend for an association was evident.
The earlier appearance of HHV-6 in the blood
compartment with respect to that of CMV does not
necessarily imply a different temporal pattern of reac-
tivation. In fact, precise dating of beta herpesvirus
reactivations may only be achieved by virologic moni-
toring at mucosal or tissue sites [34]. The rate of virus
replication may be a relevant factor in determining the
precocity of the onset of viral DNAemia. In this con-
text, we found the doubling time of HHV-6 was
around half that of CMV (0.9 versus 1.7 days), which
is in accordance with a previous estimation [35]. Otherpathogenetic factors, such as the ease of access into the
blood compartment and the relative stringency of vi-
rus-cell association, which may differ between both
beta herpesviruses, might also be of relevance.
In conclusion, our data favor the hypothesis that
a state of severe immunosuppression leads to HHV-6
and CMV coactivation, but argue against a role of
HHV-6 in predisposing the development of CMV
DNAemia or influencing the course of active CMV
infection.Nevertheless, validationof this assumption re-
quires further studies analyzing larger series of patients.ACKNOWLEDGMENTS
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